Immunome share price logo

Immunome

NASDAQ: IMNM

Mid Cap

$18.77

+0.07

(+0.37%)

as on

Immunome Stock Performance

as on November 14, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $18.14
    $18.80
    downward going graph

    3.36%

    Downside

    0.16%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $16.11
    $30.06
    downward going graph

    14.17%

    Downside

    60.15%

    Upside

    downward going graph

Immunome share price movements today

Previous Close
$18.70
Open
$18.80
Volume
488.1K
Market Cap
$2.2B
Day's Low - High
$18.14 - $18.80
52 Week Low - High
$16.11 - $30.06

Immunome Historical Returns

1 Month Return
+ 9.13 %
3 Month Return
-30.99 %
1 Year Return
+ 9.51 %
3 Year Return
+ 134.04 %
5 Year Return
+ 3.53 %

Immunome Stock Fundamentals & Key Indicators

Check Immunome market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.2B

EPS (TTM)

-2.65

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-7.05

Industry PE ratio

-13.25

PEG Ratio

-0.98

EBITDA

-279.0M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-51.33%

Immunome vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immunome with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Immunome image
Immunome
StrongBuy$2.2B3.53%-7.050.00%0.00%
Moderna image
Moderna
Neutral$100.6B0.07%-35.1828.00%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$47.5BNA68.7388.39%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$137.6B187.58%34.7885.57%0.00%
Regeneron image
Regeneron
Buy$99.2B51.37%20.2985.77%0.39%

Stock Returns calculator for Immunome Stock including INR - Dollar returns

The Immunome stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Immunome investment value today

Current value as on today

₹1,16,364

Returns

₹16,364

(+16.36%)

Returns from Immunome Stock

₹9,510 (+9.51%)

Dollar Impact

₹6,854 (+6.85%)

Analyst Recommendation on Immunome Stock

Based on 5 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 5 analysts, 100% of analysts recommend a 'BUY' rating for Immunome. Average target price of $35.13

Immunome Share Price Target

Get share price movements and forecasts by analysts on Immunome.

What analysts predicted

46.57%UPSIDE

Target Price

$35.13

Current Price

$18.77

Analyzed by

5 Analysts

High

$40

Target

$35.13

Low

$35

Immunome target price $35.13, a slight upside of 46.57% compared to current price of $18.77. According to 5 analysts rating.

Indian Investors' Interest in Immunome Stock

Search interest for Immunome Stock has decreased by -13% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-13% versus previous 30 day period

Immunome Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
2
2
2
2
4
-
-
-
-
-
Gross Profit
2
2
2
2
3
-49
-
0
-
-
Operating Income
-40
-50
-82
-44
-46
-60
-72
-59
-78
-90
EBITDA
-33
-43
-55
-40
-42
-56
-69
-53
-71
-84
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
1
1
Income Before Tax
-36
-47
-80
-41
-43
-57
-69
-53
-73
-85
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-36
-47
-80
-41
-43
-57
-69
-53
-73
-85
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
82.07%
0.00%
0.00%
0.00%
0.00%
0.00%

Immunome Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
-
14
9
6
Gross Profit
0
0
0
-
-
14
9
3
Operating Income
-7
-10
-12
-25
-36
-109
-305
-214
EBITDA
-7
-9
-17
-23
-36
-28
-151
-209
Interest Expense
0
0
0
0
0
-
-
-
Depreciation
0
0
0
0
0
0
2
2
Income Before Tax
-7
-10
-17
-24
-36
-106
-292
-212
Income Tax Expense
0
-
-
-
-
-
-
-
Net Income
-7
-10
-17
-24
-36
-106
-292
-212
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
100.00%
100.00%
57.43%

Immunome Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-36
-47
-80
-41
-43
-57
-69
-53
-73
-85
Operating Cash Flow
-23
-34
-42
-53
-49
-40
-47
-58
-61
-60
Investing Cash Flow
-81
24
9
5
-64
123
-3
-12
-304
53
Financing Cash Flow
0
0
20
162
0
45
432
0
1
2
Change in Cash
-104
-9
-12
114
-113
128
380
-70
-364
-4

Immunome Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-7
-10
-17
-24
-36
-106
-292
-212
Operating Cash Flow
-7
-9
-12
-18
-28
-7
-110
-190
Investing Cash Flow
0
0
0
0
0
-30
-85
60
Financing Cash Flow
0
10
49
27
0
116
240
640
Change in Cash
-8
0
37
9
-28
78
44
510

Global Institutional Holdings in Immunome

Check out the Institutions with significant holdings in Immunome.

Funds
Holdings
BlackRock, Inc.
7.46%
Fidelity Mt. Vernon Street Trust
6.41%
T. ROWE PRICE SMALL-CAP STOCK FUND, INC.
6.08%
Vanguard
4.92%
Theofanis Kolokotrones
3.93%
See all

Immunome News & Key Events

  • img

    Today's Timeline - 04 November

    Wed, 07:08 PM

    -

    Immunome advances varegacestat for desmoid tumors; FDA accepted NDA with action date set for April 28, 2027.

    Wed, 07:49 PM

    -

    Immunome presents initial Phase 1 data for IM-1021, showing 53% response rate in B-cell lymphoma patients.

Insights on Immunome

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, IMNM stock has moved up by 134.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 801.8% return, outperforming this stock by 792.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 201.4% return, outperforming this stock by 67.4%

About Immunome

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
OrganisationImmunome
Headquarters18702 North Creek Parkway, Bothell, WA, 98011, US
IndustryBiotechnology
CEOClay Siegall

Key Management of Immunome

Name

Title

Mr. Max Rosett

Chief Financial Officer

Dr. Robert J. Lechleider M.D.

Chief Medical Officer

Dr. Philip Tsai

Chief Technical Officer

Dr. Jack Higgins Ph.D.

Chief Scientific Officer

Ms. Sandra G. Stoneman Esq., J.D.

Chief Legal Officer, General Counsel & Corporate Secretary

Mr. Roee Shahar

Executive Vice President of Commercial

Dr. Clay B. Siegall Ph.D.

Chairman, President & CEO

FAQs

What is Immunome share price today?

Immunome share price today is $18.77 as on at the close of the market. Immunome share today touched a day high of $18.80 and a low of $18.14.

What is the 52 week high and 52 week low for Immunome share?

Immunome share touched a 52 week high of $30.06 on and a 52 week low of $16.11 on . Immunome stock price today i.e. is closed at $18.77,which is 37.56% down from its 52 week high and 16.51% up from its 52 week low.

What is Immunome's market capitalisation today?

Immunome market capitalisation is $0.00T as on .

How to invest in Immunome Stock (IMNM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immunome on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Immunome Stock (IMNM) from India?

Indian investors can start investing in Immunome (IMNM) shares with as little as ₹94.23999786376953 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹942.40 in Immunome stock (as per the Rupee-Dollar exchange rate as on ). Based on Immunome share’s latest price of $18.77 as on November 14, 2026 at 8:45 am IST, you will get 0.5328 shares of Immunome. Learn more about fractional shares .

What are the returns that Immunome has given to Indian investors in the last 5 years?

Immunome stock has given 3.53% share price returns and 25.93% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?